EUVIMEDEUVIMED entdecken
Übersichtsarbeit

IL-1–targeted therapy in dermatologic conditions

Kerem Balan, Dirk M Elston

Journal of the American Academy of Dermatology · 2026

DOI: 10.1016/j.jaad.2026.06.021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2026. Verfasst von Kerem Balan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology & Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina; Department of Dermatology and Ven…. Hauptthemen laut MEDLINE: Interleukin-1, Skin Diseases. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-1 (IL-1) plays a key role in inflammasome activation, keratinocyte signaling and neutrophil recruitment, and is a driving force behind many neutrophil-rich and suppurative dermatoses. There is robust evidence supporting the use of IL-1 blockade as a disease-modifying therapy in cryopyrin-associated periodic syndromes and other monogenic periodic fever syndromes, as well as in the treatment of Schnitzler syndrome, where it can rapidly control urticarial and neutrophilic eruptions. Cohort- and series-level data demonstrate high efficacy in IL-1 receptor antagonist deficiency and steroid-refractory pyoderma gangrenosum, whereas benefits appear more heterogeneous in hidradenitis suppurativa, pustular psoriasis and proline-serine-threonine phosphatase-interacting protein 1-associated autoinflammatory diseases. In contrast, conditions such as IL-36 receptor antagonist deficiency, synovitis acne pustulosis hyperostosis osteitis syndrome, Sweet syndrome and vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome are supported only by scattered case reports or theoretical rationale, with highly variable or uncertain responses to IL-1 blockade, highlighting the importance of careful clinical and, where possible, genetic phenotyping. We summarize practical considerations for selecting agents, pediatric and adult dosing and safety. IL-1 antagonists are indispensable for a subset of IL-1-driven disorders and represent a rational rescue option for selected neutrophilic dermatoses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1Skin DiseasesHumansSchnitzler SyndromePyoderma GangrenosumHidradenitis SuppurativaReceptors, Interleukin-1Interleukin 1 Receptor Antagonist ProteinCryopyrin-Associated Periodic SyndromesAnemia, Dyserythropoietic, CongenitalSweet SyndromePsoriasisAcne VulgarisMolecular Targeted TherapyAcquired Hyperostosis SyndromeRecombinant Fusion ProteinsHereditary Autoinflammatory Diseases

Stichwörter der Autor:innen

autoinflammatory diseasesbiological therapyhidradenitis suppurativainterleukin-1neutrophilic dermatoses

Substanzen

Interleukin-1Receptors, Interleukin-1Interleukin 1 Receptor Antagonist ProteinrilonaceptRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Dermatology & Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina; Department of Dermatology and Venereology, Etimesgut Sehit Sait Erturk State Hospital, Ankara, Turkiye.…
  • Department of Dermatology & Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina.

Zitieren

APA

Balan, K., & Elston, D. M. (2026). IL-1–targeted therapy in dermatologic conditions. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.06.021

Vancouver

Balan K, Elston DM. IL-1–targeted therapy in dermatologic conditions. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.06.021

BibTeX
@article{Balan2026,
  author = {Balan, Kerem and Elston, Dirk M},
  title = {IL-1–targeted therapy in dermatologic conditions},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  doi = {10.1016/j.jaad.2026.06.021}
}
Kostenlos starten →